KARD NASDAQ
Kardigan, Inc.
1W: -2.4%
1M: -14.6%
3M: -39.8%
YTD: -42.6%
$13.58
+0.95 (+7.52%)
Weekly Expected Move ±10.1%
$10
$12
$13
$14
$15
Credit Risk of going bust: not rated Debt: 1.2% of company value Bonds: none of note held by US funds details ▾
Not rated: insufficient price history.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.1B
52W Range12.23-27
Volume216,096
Avg Volume583,353
Beta6.05
Dividend—
Analyst Ratings
Company Info
CEOTassos Gianakakos
Employees241
SectorHealthcare
IndustryBiotechnology
IPO Date2026-06-18
Websitekardigan.bio
506 Carnegie Center Drive
Princeton, NJ 08540
US
Princeton, NJ 08540
US
(415) 573-3220
About Kardigan, Inc.
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its âCardiac Intelligenceâ platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.
Latest News
Kardigan (NASDAQ:KARD) Stock Rating Upgraded by UBS Group - MarketBeat
UBS initiates Kardigan stock with buy rating on cardiology pipeline By Investing.com - Investing.com South Africa
UBS initiates Kardigan stock with buy rating on cardiology pipeline - Investing.com
$KARD stock is down 18% today. Here's what we see in our data. - Quiver Quantitative
$KARD stock is down 18% today. Here's what we see in our data. - Quiver Quantitative
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Reinke Kristin Marie | 0 | — | 2026-09-29 | |
| Reinke Kristin Marie | A-Award | 48,368 | $14.66 | 2026-09-29 |
| PERCEPTIVE ADVISORS | A-Award | 20,706 | — | 2026-06-17 |